Tazobactam
As of the edition of 20 October 2026, Tazobactam is a small molecule: marketed, first approved in 1992 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Small molecule
- Brand name
- Zosyn
- First approved
- 2 July 1992 (FR)
- Approvals on record
- 24 in 6 regions
- Holder of the most recent approval
- B. Braun Medical; 7 holders in all
- Registered trials
- 82, 13 stopped early
- Disease areas
- Infections; Lungs and airways; Blood and lymph; Cancer; Inherited and neonatal; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 28 | 13 | 3 | 3 |
| Phase 1 | 9 | 7 | 0 | 0 |
| Phase 2 | 10 | 7 | 0 | 3 |
| Phase 3 | 16 | 10 | 2 | 2 |
| Phase 4 | 19 | 8 | 2 | 5 |
| All trials | 82 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Applicant and Lead sponsor of trials | 2001 to now |
| Taiho | Applicant | 2008 to now |